Lupin Launches Generic Bridion, Threatening Merck's Muscle Relaxant Reversal Franchise
MRK sits 67% above its 52-week low of $77.53 on light trading volume (0.3× avg).
Summary
Lupin has launched a generic version of Merck's Bridion (sugammadex) in the U.S. after FDA approval, directly competing with Merck's neuromuscular blockade reversal agent. Bridion is a significant product; generic entry typically erodes branded sales rapidly. This launch comes as the U.S. plans tariffs on imported generics starting August 2028, which could eventually impact pricing dynamics but does not mitigate the immediate competitive threat. Merck's recent pipeline successes (Keytruda combinations, LIPFENDRA) provide offsets, but this generic competition adds a headwind to the established portfolio.
At the time of this announcement, MRK was trading at $129.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $319.1B. The 52-week trading range was $77.53 to $135.05. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.